PDL BioPharma, Inc. (NASDAQ:PDLI)
A biopharmaceutical company focused on discovering, developing and commercializing innovative therapies for severe or life-threatening illnesses.
- Quote
- Commentary
- Scorecard
- Historical Prices
- Chart
- Stats
- Ratios
- Earnings/Growth Rates
- Statements
- SEC Filings
Recs
Coralreefer1
(36.26)
Submitted: 2/7/2012 8:45:42 AM :
Start Price:
$6.44
PDLI Score:
+1.56
reliance on one product and its dividend has lessed over time. "Not good to put your apples in JUST one basket"
Recs
nveagle
(< 20)
Submitted: 1/18/2012 12:22:04 PM :
Start Price:
$6.28
PDLI Score:
-2.46
Potential in the long term.
Recs
jimscottage11
(< 20)
Submitted: 12/22/2011 10:01:43 AM :
Start Price:
$6.13
PDLI Score:
-4.53
High quarterly dividend.(10% yearly) Patents expire in 2015 though.
Recs
ThePoulTrend
(82.67)
Submitted: 11/11/2011 9:28:19 AM :
Start Price:
$5.98
PDLI Score:
-1.01
Serious Dividend!
Recs
stockstar69
(23.56)
Submitted: 11/10/2011 12:44:19 PM :
Start Price:
$5.95
PDLI Score:
-2.25
Decent dividend. An inovative company and competive in its field.
Recs
titans8904
(42.46)
Submitted: 9/27/2011 10:11:42 AM :
Start Price:
$5.72
PDLI Score:
-2.92
Great company
Recs
maniacdog
(< 20)
Submitted: 7/15/2011 3:57:40 PM :
Start Price:
$5.91
PDLI Score:
+4.27
I bought 550 shares in real life today I hope I am right.
Recs
Recs
CushCap
(24.05)
Submitted: 7/14/2011 10:09:03 AM :
Start Price:
$6.08
PDLI Score:
+2.62
Klarman doubled down earlier this year, and won right to pursue lawsuit in Nevada courts. Importantly, they didn't win the lawsuit yet, but the court deemed it valid: a small step in a process that could lead to tremendous upside. And in the event that this doesn't happen there appears to be enought value in their existing business (even though it is in terminal decline) to support their stock price. I am very early in my research, but this is my general understanding of the investment case so far.
Recs
Recs
Recs
EclecticRecluse
(76.50)
Submitted: 5/25/2011 10:01:35 AM :
Start Price:
$6.00
PDLI Score:
+3.44
Good Forward Earnings Estimate
Recs
MichaelHamilton
(97.59)
Submitted: 5/19/2011 6:19:26 PM :
Start Price:
$6.04
PDLI Score:
-4.72
garbage
Recs
marketprofile01
(74.58)
Submitted: 5/14/2011 7:11:38 PM :
Start Price:
$5.90
PDLI Score:
+6.55
beaupost beat
Recs
zlot
(73.66)
Submitted: 5/2/2011 4:24:09 PM :
Start Price:
$6.01
PDLI Score:
+6.41
I like cheap(<$15) dividend-producing stocks. This has a pretty good record, and although it's currently heavily shorted, I still think it's going to be great for my retirement.
Recs
paola145
(28.34)
Submitted: 4/16/2011 9:45:40 PM :
Start Price:
$5.76
PDLI Score:
+6.93
They pay an excellent dividend and their intellectual property continues to be used by others.
Recs
healthcarevalue
(95.79)
Submitted: 3/30/2011 11:05:05 AM :
Start Price:
$5.21
PDLI Score:
+20.13
Market cap of 785 million, combined with price/earnings of 10.37, leaves room to move and/or be acquired. Long term debt is very low, debt/equity negligible. Dividend yield of 10.90 percent is very attractive.
Recs
SnowBawl
(< 20)
Submitted: 3/23/2011 8:36:30 AM :
Start Price:
$5.12
PDLI Score:
+19.41
Yahoo small cap growth
Recs
Recs
marketbeater80
(22.80)
Submitted: 2/27/2011 9:02:46 PM :
Start Price:
$4.71
PDLI Score:
+33.22
From Seekingalpha,
"This biotech play has seen better days. Shares traded above $30 back in 2006, but now trade for less than $5. Klarman originally owned this stock back in 2008, but sold off his stake in the summer of 2009 at a loss. Shares have drifted yet lower since then, leading Klarman to jump back in, buying 5.6 million shares in the last quarter, which are currently worth about $30 million.
PDL holds the patent to a number of antibody technologies that are used by other drug companies with their drugs. Klarman's latest buy comes at a time when the company is pursuing a potentially large legal settlement. PDL is seeking unpaid royalties from Roche's Genentech division. Some suspect that Genentech may be liable for hundreds of millions in royalty payments if PDL prevails in a current lawsuit.
Besides this potentially big upside event, PDL typically generates $300 to $400 million a year in sales and earns roughly $1 a share. Not bad for a $5 stock. Shares are so cheap because PDL's key intellectual property rights will lose patent protection in 2014. To offset that cliff, the company is working on a range of new drugs that are currently undergoing clinical trials.
Shares are also being discounted after PDL agreed to pay"
RSS Headlines
Fool UK
- Show Me:
-
Outperform
-
Underperform
-
All
- Sort by:
-
Author
-
Recs
-
Date
-
Member Rating
-
Results 1 - 20 of 128 : 1 2 3 4 5 6 7 Next »